Evaluation Sub-Committee - Applications considered

• 1523.1 - Transluminal insertion, management, repositioning and removal of intravascular microaxial blood pump (Impella) for patients requiring mechanical circulatory support
• 1662.2 - The reduction of mitral regurgitation through tissue approximation using transvenous/transeptal techniques
• 1677.1 - Pharmacy Diabetes Screening Trial (PDST)
• 1686.1 - ¹⁷⁷ Lutetium PSMA i&t for metastatic castrate resistant prostate cancer
• 1708 - RNA PCR testing to determine eligibility and treatment for PBS-subsidised bulevirtide (HEPCLUDEX) for treatment of Hepatitis Delta Virus
• 1712 - Out-of-laboratory Sleep Studies in the Diagnosis and Management of Sleep Disordered Breathing in Children & Adolescents
• 1713 - Cardiac MRI in the diagnosis of myocarditis
• 1720 - ⁶⁸Ga PSMA-11 PET/CT imaging for patients who are candidates for PSMA targeted therapy
• 1722.1 - Axicabtagene ciloleucel (YESCARTA®) for relapsed or refractory large B-cell lymphoma
• 1741 - Continuous Nerve Blockade using a catheter technique
• 1749 – Insertion of durable ventricular assist device (VAD) for use as destination therapy
• 1758 - Expansion of MBS item numbers 12320 & 12322 for bone mineral density (BMD) testing to include patients aged 60-69 years
• 1764 - Micro-bypass glaucoma surgery device implantation into the suprachoroidal space as a standalone procedure in patients with open angle glaucoma

Consultation Input:

MSAC values consultation input from individuals and organisations with an interest in an application that it is considering, including experience of the medical conditions, services or technologies being addressed by the application.

It is anticipated that the above-mentioned applications will proceed to MSAC in April 2024. Consultation input closed Friday, 16 February 2024.

Further information on MSAC’s consultation process is also available on the MSAC website.